# DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)

Clinical trial · Diakonos Oncology Corporation

- Archive id: nct:NCT06805305
- Published: 2025-02-03
- Venue: ClinicalTrials.gov
- ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT06805305
- Source URL: https://clinicaltrials.gov/study/NCT06805305
- Provenance: clinicaltrials

## Abstract

The goal of this clinical trial is to learn if DOC1021 + pIFN alongside standard of care (SOC) will improve survival in adult patients newly diagnosed with glioblastoma (IDH-wt). It will also evaluate the safety of DOC1021 + pIFN. Researchers will compare DOC1021 dendritic cell immunotherapy regimen added to SOC compared to SOC treatment alone. Participants in the DOC1021 + pIFN + SOC arm will: \* Take filgrastim subcutaneously x 5 doses and subsequently undergo a leukapheresis collection \* Undergo ultrasound guided perinodal DOC1021 injections every 2 weeks for a total of 3 doses \* Receive subcutaneous pIFN injections weekly for a total of 6 doses in parallel with the DOC1021 injections Both arms of the trial will: \\- Visit the clinic regularly to assess quality of life, symptoms, medication use, imaging, bloodwork, and to receive SOC treatment with surgery, temozolomide chemotherapy and radiation

_Abstract reproduced under ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters._

## Trial details

- status: RECRUITING
- phase: PHASE2
- study type: INTERVENTIONAL
- enrollment: 180
- sponsor: Diakonos Oncology Corporation
- conditions: Glioblastoma (GBM)
- interventions: BIOLOGICAL: DOC1021; PROCEDURE: Tumor resection; DRUG: Temodar (Temozolomide); RADIATION: SOC cranial radiation
- start date: 2025-03-17
- start date type: ACTUAL
- primary completion date: 2030-03-01
- has results: false
- data source: ClinicalTrials.gov
- data processed: 2026-10-29T09:00:05
- modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters

Topics: [mRNA Therapeutics & Cancer Vaccines](https://space-kitty.com/topics/mrna-cancer-vaccines)

---
Space Kitty Archive · https://space-kitty.com · API: https://space-kitty.com/api/v1 · MCP: https://space-kitty.com/mcp · Premium: $0.20/request via x402 (Base Sepolia (testnet)). Metadata: arXiv (CC0), OpenAlex (CC0), Europe PMC (CC BY/CC0 works), ClinicalTrials.gov.